Lonza invests CHF500m in Large-Scale Facility in Stein (CH)
Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Since establishing drug product development and manufacturing services in 2016, Lonza has expanded its clinical drug product offering in Basel, Stein and Visp (CH), and Guangzhou (CN). With its newest significant investment in commercial drug product manufacturing Lonzas adds on its strategic commitment to offer an integrated end-to-end service. The investment will enable the company to provide "customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply", the company announced.
The new flexible facility will be constructed in Stein (CH) on the same campus as Lonzas current clinical drug product facility, where compunds as such are produced, allowing the company to leverage the existing infrastructure, capabilities and talent. At the location south to river Rhein also Novartis Pharma and Snygenta Corp. are established with production plants (photo). The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026.
Pierre-Alain Ruffieux, CEO, Lonza, commented: This strategic investment completes our offering in drug product and strengthens our position as a leading CDMO with an unparalleled breadth of offerings across scales and technologies. Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle.
©EuropeanBiotechNews/gkä
Biocytogen Co Ltd
Draupnir Bio ApS